MSME (Udyam registered) Ministry of MSME
- Udyam number
- UDYAM-HR-18-0002459
Market Cap
₹4.27 Cr
FABINO · BSE
Share Price
₹20.31
0.00% today
Revenue
₹20.84 Cr
FY 2025-26 · +15.5% YoY
EBITDA
−₹2.06 Cr
Margin -9.9%
Net Profit
−₹0.56 Cr
FY 2025-26 · -900.0% YoY
P/E (TTM)
69.9x
P/B 1.0x
Authorised capital
₹12 Cr
Registered with MCA
Paid-up capital
₹2.1 Cr
Issued & subscribed
About Fabino Enterprises Limited
Data last updated:
Fabino Enterprises Limited is a public limited company based in Sonipat, Haryana, India. It operates in the ayurvedic products and services segment of the healthcare sector. It was incorporated on 27 October 2011 and has been in existence for over 15 years.
The company is registered with the Registrar of Companies (ROC), Haryana, under CIN L24100HR2011PLC114093. Its GSTIN is 06AABCF8473C1ZR (Haryana). It is a listed company as per MCA records. Its shares are listed on BSE: 543444.
The company has an authorised share capital of ₹12 Cr and a paid-up capital of ₹2.1 Cr. It was formerly known as Fabino Life Sciences Private Limited. It is led by directors including Aditya Mahavir Jain (Managing Director) and Tesu Alakh.
Its last annual general meeting (AGM) was held on 22 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Jeevan Vihar Extension Near Shubham Garden, Murthal Road Sonipat, Haryana, India – 131001.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹20.84 Cr, a growth of 15.5% compared to the previous year. For the same year it recorded a net loss of ₹56 Lakh (net margin -2.7%) and EBITDA of -₹2.06 Cr (EBITDA margin -9.9%). The net worth stands at ₹3.65 Cr (down 13.1% YoY). Total assets are valued at ₹5.27 Cr (down 12.2% YoY).
The company is associated with 1 brand: Fabino Life. As per MCA filings, the company has satisfied charges of ₹2.35 Cr on record. Court records list 1 case involving the company, including 1 filed against it; 1 case is pending. The company has 35 deals on record (32 market trades, 1 ipo, 1 funding round), with disclosed funding of ₹50 Lakh; the latest was in April 2026. Its 6 peer companies in the Healthcare industry (Ayurvedic Products and Services), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 2 smaller; the largest is Ayukalp Uap Pharma Private Limited with revenue of ₹19.05 Cr.
Fabino Enterprises Limited is registered as an MSME under the Udyam registration framework (Reg. No. UDYAM-HR-18-0002459). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website fabinolife.com.
Company details
CIN L24100HR2011PLC114093
Registration Number 114093
Incorporation Date 27 October 2011
ROC Haryana
Listing Status Listed - Listed on BSE (543444)
Company Status Active
Date of Last AGM 22 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification MSME
Udyam Registration UDYAM-HR-18-0002459
CIN history
Fabino Enterprises has 3 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24100HR2011PLC114093, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24100HR2011PLC114093 | Current |
| U24100DL2011PLC226781 | Previous |
| L24100DL2011PLC226781 | Previous |
| U24100DL2011PTC226781 | Previous |
Recognitions & Rankings of Fabino Enterprises
Contact details
Fabino Enterprises Limited's registered office is in Sonipat, Haryana. Its website is fabinolife.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressJeevan Vihar Extension Near Shubham Garden, Murthal Road Sonipat, Haryana, India – 131001
- IndustryHealthcare, Ayurvedic Products & Services
To see the full contact details of Fabino Enterprises Limited, buy the company report.
Comprehensive company report
Fabino Enterprises Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Fabino Enterprises operates one associated brand: Fabino Life. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Manufacturer of allopathic and herbal medicine products | fabinolife.com |
Business activity
The main business activity of Fabino Enterprises is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Fabino Enterprises Limited, buy the company report.
Financials of Fabino Enterprises Limited
FY 2025-26 filings availableFabino Enterprises Limited reported revenue of ₹20.84 Cr (up 15.5% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹20.84 Cr
+15.5% YoY
EBITDA
−₹2.06 Cr
-1816.7% YoY
Profit After Tax
−₹0.56 Cr
-900.0% YoY
Net Worth
₹3.65 Cr
-13.1% YoY
Total Assets
₹5.27 Cr
-12.2% YoY
Total Debt
₹1.62 Cr
-9.5% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 20.84 | 18.04 | 21.08 | 3.36 |
| Revenue growth | +15.5% | -14.4% | +527.4% | - |
| EBITDA | (2.06) | 0.12 | 0.12 | 0.04 |
| EBITDA margin | -9.9% | +0.7% | +0.6% | +1.2% |
| Profit before tax | (0.74) | 0.20 | 0.05 | 0.02 |
| Net profit | (0.56) | 0.07 | 0.04 | 0.02 |
| Net profit margin | -2.7% | +0.4% | +0.2% | +0.6% |
| EPS (₹) | (2.66) | 0.29 | 0.17 | 0.05 |
| Balance sheet | ||||
| Total assets | 5.27 | 6.00 | 5.46 | 4.57 |
| Net worth | 3.65 | 4.20 | 4.14 | 4.11 |
| Total debt | 1.62 | 1.79 | 1.27 | 0.41 |
| Cash & bank | 0.20 | 0.24 | 0.06 | 0.24 |
| Net working capital | 4.66 | 5.37 | 5.02 | 4.34 |
| Cash flow | ||||
| Cash from operations | 0.19 | 0.12 | (0.77) | (0.68) |
| Cash from investing | 0.07 | (0.29) | (0.28) | (0.01) |
| Cash from financing | (0.30) | 0.35 | 0.86 | 0.34 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 11.43 | 18.04 | 6.08 | 3.36 | 4.20 | 3.06 | 7.52 |
| Revenue growth | -36.6% | +196.7% | +81.0% | -20.0% | +37.3% | -59.3% | - |
| EBITDA | (1.54) | 0.17 | 0.11 | 0.04 | 0.10 | 0.05 | 0.32 |
| EBITDA margin | -13.5% | +0.9% | +1.8% | +1.2% | +2.4% | +1.6% | +4.3% |
| Profit before tax | (0.47) | 0.26 | 0.06 | 0.02 | 0.07 | 0.02 | 0.10 |
| Net profit | (0.35) | 0.13 | 0.05 | 0.02 | 0.05 | 0.01 | 0.07 |
| Net profit margin | -3.1% | +0.7% | +0.8% | +0.6% | +1.2% | +0.3% | +0.9% |
| EPS (₹) | (1.71) | 0.63 | 0.23 | 0.05 | 0.22 | 0.25 | 4.59 |
| Balance sheet | |||||||
| Total assets | 5.04 | 5.90 | 5.04 | 4.57 | 4.22 | 1.70 | 1.90 |
| Net worth | 3.93 | 4.29 | 4.16 | 4.11 | 4.10 | 1.30 | 0.67 |
| Total debt | 1.11 | 1.61 | 0.84 | 0.41 | 0.05 | 0.31 | 1.08 |
| Cash & bank | 0.16 | 0.22 | 0.02 | 0.24 | 0.59 | 0.07 | 0.17 |
| Net working capital | 4.46 | 5.32 | 4.66 | 4.34 | 3.95 | 1.47 | 1.24 |
| Cash flow | |||||||
| Cash from operations | 0.59 | (0.12) | (2.99) | (0.68) | (1.90) | (0.45) | 2.44 |
| Cash from investing | (0.01) | (0.29) | (0.18) | (0.01) | (0.05) | (0.10) | 0.00 |
| Cash from financing | (0.63) | 0.61 | 0.43 | 0.34 | 2.47 | 0.45 | (2.37) |
| Particulars | Sep 2021 | Jun 2021 |
|---|---|---|
| Revenue | 0.92 | 1.13 |
| Other income | 0.01 | 0.00 |
| Total expenses | 1.00 | 1.10 |
| EBITDA | (0.08) | 0.03 |
| EBITDA margin | -8.7% | +2.7% |
| Depreciation | (0.01) | 0.01 |
| Interest | 0.00 | 0.00 |
| Profit before tax | (0.06) | 0.02 |
| Tax | (0.01) | 0.01 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 29 Oct 2026
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Revenue | 20.84 | 18.04 | 21.08 | 3.36 |
| Revenue growth | +15.5% | -14.4% | +527.4% | - |
| Other income | 1.56 | 0.29 | 0.01 | 0.02 |
| Total expenses | 22.90 | 17.92 | 20.96 | 3.32 |
| Employee cost | 0.00 | 0.28 | 0.18 | 0.19 |
| EBITDA | (2.06) | 0.12 | 0.12 | 0.04 |
| EBITDA margin | -9.9% | +0.7% | +0.6% | +1.2% |
| Depreciation | 0.11 | 0.08 | 0.04 | 0.03 |
| Interest | 0.13 | 0.13 | 0.04 | 0.01 |
| Profit before tax | (0.74) | 0.20 | 0.05 | 0.02 |
| Tax | (0.18) | 0.13 | 0.01 | 0.00 |
| Net profit | (0.56) | 0.07 | 0.04 | 0.02 |
| Net profit margin | -2.7% | +0.4% | +0.2% | +0.6% |
| EPS (₹) | (2.66) | 0.29 | 0.17 | 0.05 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Equity & liabilities | ||||
| Share capital | 2.10 | 2.10 | 2.10 | 2.10 |
| Reserves & surplus | 1.55 | 2.10 | 2.04 | 2.01 |
| Shareholders' funds (net worth) | 3.65 | 4.20 | 4.14 | 4.11 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 0.11 | 0.14 | 0.00 | 0.00 |
| Unsecured loans | 1.51 | 1.65 | 1.27 | 0.41 |
| Total debt | 1.62 | 1.79 | 1.27 | 0.41 |
| Total liabilities | 5.27 | 6.00 | 5.46 | 4.57 |
| Assets | ||||
| Gross block | 0.78 | 0.89 | 0.59 | 0.15 |
| Net block | 0.37 | 0.55 | 0.34 | 0.15 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 1.06 | 1.20 | 1.33 | 1.19 |
| Sundry debtors | 16.46 | 14.17 | 12.61 | 2.53 |
| Cash & bank balances | 0.20 | 0.24 | 0.06 | 0.24 |
| Loans & advances | 3.81 | 1.42 | 0.92 | 0.82 |
| Total current assets | 21.53 | 17.03 | 14.92 | 4.78 |
| Total current liabilities | 16.87 | 11.66 | 9.90 | 0.44 |
| Net working capital | 4.66 | 5.37 | 5.02 | 4.34 |
| Total assets | 5.27 | 6.00 | 5.46 | 4.57 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Opening cash | 0.24 | 0.06 | 0.24 | 0.59 |
| Net cash from operating activities | 0.19 | 0.12 | (0.77) | (0.68) |
| Net cash from investing activities | 0.07 | (0.29) | (0.28) | (0.01) |
| Net cash from financing activities | (0.30) | 0.35 | 0.86 | 0.34 |
| Net change in cash | (0.05) | 0.18 | (0.18) | (0.35) |
| Closing cash | 0.20 | 0.24 | 0.06 | 0.24 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Growth | ||||
| Sales growth | +15.5% | -14.4% | +527.4% | - |
| EBITDA growth | -1816.7% | 0.0% | +200.0% | - |
| PBT growth | - | +300.0% | +150.0% | +9997.0% |
| Net income growth | -900.0% | +75.0% | +100.0% | - |
| Revenue CAGR (3Y) | +83.7% | - | - | - |
| Profitability & leverage | ||||
| Net income margin | -2.7% | +0.4% | +0.2% | +0.6% |
| Return on capital employed | - | +5.6% | +1.8% | +0.4% |
| Return on net worth | - | +1.4% | +1.0% | +0.2% |
| Debt / equity | - | 0.37 | 0.20 | 0.10 |
| Long-term debt / equity | - | 0.37 | 0.20 | 0.10 |
| Interest cover | -5.99 | 325.00 | 50.00 | 100.00 |
| Efficiency & per share | ||||
| Fixed asset turnover | - | 24.54 | 56.97 | 22.40 |
| Inventory turnover | - | 14.26 | 16.73 | 2.82 |
| Debtors turnover | - | 1.35 | 2.78 | 1.33 |
| EPS (₹) | (2.66) | 0.29 | 0.17 | 0.05 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 20.02 | 19.73 | 19.59 |
| Particulars | Sep 2021 | Jun 2021 |
|---|---|---|
| Revenue | 0.92 | 1.13 |
| Other income | 0.01 | 0.00 |
| Total expenses | 1.00 | 1.10 |
| EBITDA | (0.08) | 0.03 |
| EBITDA margin | -8.7% | +2.7% |
| Depreciation | (0.01) | 0.01 |
| Interest | 0.00 | 0.00 |
| Profit before tax | (0.06) | 0.02 |
| Tax | (0.01) | 0.01 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 11.43 | 18.04 | 6.08 | 3.36 | 4.20 | 3.06 | 7.52 |
| Revenue growth | -36.6% | +196.7% | +81.0% | -20.0% | +37.3% | -59.3% | - |
| Other income | 1.30 | 0.29 | 0.00 | 0.02 | 0.01 | 0.00 | 0.00 |
| Total expenses | 12.97 | 17.87 | 5.97 | 3.32 | 4.10 | 3.01 | 7.20 |
| Employee cost | 0.00 | 0.27 | 0.16 | 0.19 | 0.19 | 0.09 | 0.21 |
| EBITDA | (1.54) | 0.17 | 0.11 | 0.04 | 0.10 | 0.05 | 0.32 |
| EBITDA margin | -13.5% | +0.9% | +1.8% | +1.2% | +2.4% | +1.6% | +4.3% |
| Depreciation | 0.10 | 0.07 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 |
| Interest | 0.13 | 0.13 | 0.02 | 0.01 | 0.01 | 0.01 | 0.20 |
| Profit before tax | (0.47) | 0.26 | 0.06 | 0.02 | 0.07 | 0.02 | 0.10 |
| Tax | (0.12) | 0.13 | 0.01 | 0.00 | 0.02 | 0.01 | 0.03 |
| Net profit | (0.35) | 0.13 | 0.05 | 0.02 | 0.05 | 0.01 | 0.07 |
| Net profit margin | -3.1% | +0.7% | +0.8% | +0.6% | +1.2% | +0.3% | +0.9% |
| EPS (₹) | (1.71) | 0.63 | 0.23 | 0.05 | 0.22 | 0.25 | 4.59 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 2.10 | 2.10 | 2.10 | 2.10 | 2.10 | 1.20 | 0.15 |
| Reserves & surplus | 1.83 | 2.19 | 2.06 | 2.01 | 2.00 | 0.10 | 0.52 |
| Shareholders' funds (net worth) | 3.93 | 4.29 | 4.16 | 4.11 | 4.10 | 1.30 | 0.67 |
| Secured loans | 0.11 | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 1.00 | 1.47 | 0.84 | 0.41 | 0.05 | 0.31 | 1.08 |
| Total debt | 1.11 | 1.61 | 0.84 | 0.41 | 0.05 | 0.31 | 1.08 |
| Total liabilities | 5.04 | 5.90 | 5.04 | 4.57 | 4.22 | 1.70 | 1.90 |
| Assets | |||||||
| Gross block | 0.78 | 0.77 | 0.48 | 0.15 | 0.35 | 0.35 | 0.22 |
| Net block | 0.37 | 0.47 | 0.24 | 0.15 | 0.17 | 0.16 | 0.08 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.05 | 0.05 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.93 | 1.20 | 1.33 | 1.19 | 1.71 | 0.47 | 0.29 |
| Sundry debtors | 12.68 | 8.62 | 6.22 | 2.53 | 1.44 | 1.33 | 2.33 |
| Cash & bank balances | 0.16 | 0.22 | 0.02 | 0.24 | 0.59 | 0.07 | 0.17 |
| Loans & advances | 2.97 | 2.38 | 1.55 | 0.82 | 0.62 | 0.16 | 0.13 |
| Total current assets | 16.74 | 12.42 | 9.12 | 4.78 | 4.36 | 2.03 | 2.92 |
| Total current liabilities | 12.28 | 7.10 | 4.46 | 0.44 | 0.41 | 0.56 | 1.68 |
| Net working capital | 4.46 | 5.32 | 4.66 | 4.34 | 3.95 | 1.47 | 1.24 |
| Total assets | 5.04 | 5.90 | 5.04 | 4.57 | 4.22 | 1.70 | 1.90 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.22 | 0.02 | 0.24 | 0.59 | 0.07 | 0.17 | 0.10 |
| Net cash from operating activities | 0.59 | (0.12) | (2.99) | (0.68) | (1.90) | (0.45) | 2.44 |
| Net cash from investing activities | (0.01) | (0.29) | (0.18) | (0.01) | (0.05) | (0.10) | 0.00 |
| Net cash from financing activities | (0.63) | 0.61 | 0.43 | 0.34 | 2.47 | 0.45 | (2.37) |
| Net change in cash | (0.05) | 0.20 | (2.75) | (0.35) | 0.52 | (0.10) | 0.07 |
| Closing cash | 0.16 | 0.22 | 0.02 | 0.24 | 0.59 | 0.07 | 0.17 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -36.6% | +196.7% | +81.0% | -20.0% | +37.3% | -59.3% | - |
| EBITDA growth | -1005.9% | +54.6% | +175.0% | -60.0% | +100.0% | -84.4% | - |
| PBT growth | - | +333.3% | +200.0% | -71.4% | +250.0% | -80.0% | +9997.0% |
| Net income growth | -369.2% | +160.0% | +150.0% | -60.0% | +400.0% | -85.7% | - |
| Revenue CAGR (3Y) | +50.4% | +62.6% | +25.7% | -23.6% | +15.0% | - | - |
| EBITDA CAGR (3Y) | - | +19.4% | +30.1% | -50.0% | -32.1% | - | - |
| Profitability & leverage | |||||||
| Net income margin | -3.1% | +0.7% | +0.8% | +0.6% | +1.2% | +0.3% | +0.9% |
| Return on capital employed | - | +7.1% | +1.9% | +0.5% | +2.7% | +2.8% | +11.5% |
| Return on net worth | - | +3.1% | +1.2% | +0.2% | +1.9% | +3.1% | +11.0% |
| Debt / equity | - | 0.29 | 0.15 | 0.05 | 0.06 | 0.70 | 2.83 |
| Long-term debt / equity | - | 0.29 | 0.15 | 0.05 | 0.06 | 0.70 | 0.96 |
| Interest cover | -7.93 | 130.00 | 25.00 | 100.00 | 14.29 | 33.33 | 66.67 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 28.86 | 19.30 | 13.44 | 12.00 | 10.74 | 34.18 |
| Inventory turnover | - | 14.26 | 4.83 | 2.32 | 3.85 | 8.05 | 2.88 |
| Debtors turnover | - | 2.41 | 1.39 | 1.69 | 3.03 | 1.67 | 3.08 |
| EPS (₹) | (1.71) | 0.63 | 0.23 | 0.05 | 0.22 | 0.25 | 4.59 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 20.42 | 19.80 | 19.59 | 19.54 | 10.86 | 44.84 |
To see the full year-wise statements and ratios of Fabino Enterprises Limited, buy the company report.
Board of directors of Fabino Enterprises Limited
Fabino Enterprises has 9 current directors and 13 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Tesu Alakh | Director | 27 Oct 2021 | 5 Years 0 Months | Current |
| Aditya Mahavir Jain | Managing Director | 06 Dec 2021 | 4 Years 10 Months | Current |
| Arihant Jain Also directs: JPJ Offshores Private Limited | Director | 14 Jan 2021 | 5 Years 9 Months | Current |
| Sumit Malik Also directs: Upender Metaplast Private Limited | Director | 22 Sep 2022 | 4 Years 1 Months | Current |
| Deepali Singla | Additional Director | 26 Dec 2025 | 0 Years 10 Months | Current |
| Vandana Jain Also directs: Vaksons Metaplast Private Limited | Director | 28 Aug 2025 | 1 Years 2 Months | Current |
Showing 6 of 9 current directors. View all directors
Peer comparison
Fabino Enterprises Limited is compared with the 6 companies closest to it by revenue in the Healthcare industry (Ayurvedic Products and Services), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Fabino Enterprises Limitedthis company | ₹20.84 Cr (FY 2026) | -₹56 Lakh | -2.7% | 15.5% | Sonipat, Haryana, India | |
| Ayukalp Uap Pharma Private Limited | ₹19.05 Cr (FY 2025) | 5.0% | Ahmedabad, Gujarat, India | |||
| Sahyadri Ayurvedic Life Private Limited | ₹18.85 Cr (FY 2025) | -5.0% | Satara, Maharashtra, India | |||
| Herbal Strategi Homecare Private Limited | ₹18.74 Cr (FY 2025) | 19.0% | Bangalore, Karnataka, India | |||
| Hindustan Herbals Limited | ₹18.64 Cr (FY 2020) | 41.0% | New Delhi, Delhi, India | |||
| Dhathri Life Sciences Private Limited | ₹18.11 Cr (FY 2024) | 9.0% | Kayamkulam, Kerala, India | |||
| Veerhealth Care Limited | ₹17.89 Cr (FY 2025) | 22.0% | Mumbai, Maharashtra, India |
To see the full peer comparison of Fabino Enterprises Limited, buy the company report.
Auditor
Fabino Enterprises Limited is audited by D G M S & Co. for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| D G M S & Co. | FY 2023 | 0112187W |
Shareholding
Shareholding for the quarter ended Jun 2026: promoters hold 56.80%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 43.20%.
Jun 2026
QUARTER
56.80% Promoters
43.20% Retail & Others
Promoter holding - history
Now 56.80% · Jun 2026High 56.80% · Dec 2025Low 56.80% · Dec 2025
Shareholding trend - last 6 quarters
| Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|
| Promoters | 56.80% | 56.80% | 56.80% |
| Public | 43.20% | 43.20% | 43.20% |
Charges & borrowings
Open charges
None
Satisfied charges
₹2.35 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 29 Dec 2015 | 10628373 | Punjab National Bank | ₹2.35 Cr | Satisfied |
To see the full charge records of Fabino Enterprises Limited, buy the company report.
Total charge records: 1 View all charges
Deals & funding
Fabino Enterprises Limited has 35 deals on record (32 market trades, 1 ipo, 1 funding round), with disclosed funding of ₹50 Lakh; the latest was in April 2026.
Total deals
35
Market trades
32
IPO
1
Funding round
1
Secondary share transfer
1
Disclosed funding
₹50 Lakh
Deals on record (5 of 35)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Apr 2026 | Market trade | ₹33.7 Lakh | Buyer: an individual Seller: Venkateshwara Industrial Promotion Co. Ltd , Emrald Commercial Limited , 2 individuals |
| Mar 2026 | Market trade | ₹4.4 Lakh | Buyer: an individual Seller: Altizen Ventures LLP |
| Mar 2026 | Market trade | ₹10.4 Lakh | Buyer: Altizen Ventures LLP , an individual Seller: 2 individuals |
| Feb 2026 | Market trade | ₹10.7 Lakh | Buyer: 2 individuals Seller: Altizen Ventures LLP |
| Jan 2026 | Market trade | ₹13.4 Lakh | Buyer: Altizen Ventures LLP , an individual Seller: an individual |
To see the full deal history of Fabino Enterprises Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Fabino Enterprises Limited has 1 court case on record: 1 filed against it. All case is pending.
Total cases
1
Filed against the company
1
Pending
1
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 1 | 1 | 1 |
Cases on record (1 of 1)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Chandigarh | Court case (CS CJ) | Filed against the company by M/S D.M. Pharma | Pending |
To see the full case history of Fabino Enterprises Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Fabino Enterprises Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Fabino Enterprises has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 06AABCF8473C1ZR | Haryana | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Fabino Enterprises Limited, buy the company report.
Recent activity
Fabino Enterprises Limited has 23 board changes on record since 2019: 16 appointments and 7 cessations. The latest: Rahul Mangla was appointed as Additional Director on 29 Sep 2026.
Appointed
Rahul Mangla was appointed as Additional Director.
Appointed
Samrat Vardhan Dutta was appointed as Additional Director.
Appointed
Sarthak Goyal was appointed as Additional Director.
Filing
Fabino Enterprises Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Haryana.
Appointed
Deepali Singla was appointed as Additional Director.
AGM
Fabino Enterprises Limited last Annual general meeting of members was held on 22 Sep 2025 as per latest MCA records.
Ceased
Vandana Jain ceased to be Additional Director.
Appointed
Vandana Jain was appointed as Director.
Ceased
Jitender Kumar ceased to be Director.
Appointed
Nitin Mehra was appointed as Additional Director.
Ceased
Gagan Gupta ceased to be Director.
Appointed
Jitender Kumar was appointed as Director.
16 earlier events are in the company report.
Frequently asked questions
Fabino Enterprises is an active public limited company based in Sonipat, Haryana, India. The company works in ayurvedic products and services, within the healthcare industry. It was incorporated on 27 October 2011 (15+ years old) and is registered under CIN L24100HR2011PLC114093. Listed on BSE: 543444.
Fabino Enterprises reported revenue of ₹20.84 Cr for FY 2025-26 (up 15.5% YoY) based on consolidated financials.
Fabino Enterprises has 9 current directors:
- Aditya Mahavir Jain - Managing Director
- Tesu Alakh - Director
- Arihant Jain - Director
- Sumit Malik - Director
- Deepali Singla - Additional Director
- Vandana Jain - Director
- Rahul Mangla - Additional Director
- Sarthak Goyal - Additional Director
- Samrat Vardhan Dutta - Additional Director
The latest financial statements of Fabino Enterprises on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 22 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Fabino Enterprises is 06AABCF8473C1ZR, registered in Haryana.
The CIN (Corporate Identification Number) of Fabino Enterprises is L24100HR2011PLC114093. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Fabino Enterprises is a listed company as per MCA records. Its shares are listed on BSE (code: 543444).
Fabino Enterprises has 1 court case on record: 1 filed against it. 1 is pending.
Fabino Enterprises was incorporated on 27 October 2011, making it 15+ years old. It is registered with the Registrar of Companies, Haryana.
Fabino Enterprises has 35 deals on record (32 market trades, 1 ipo, 1 funding round), with disclosed funding of ₹50 Lakh; the latest was in April 2026.
The peers of Fabino Enterprises by revenue are Ayukalp Uap Pharma Private Limited, Sahyadri Ayurvedic Life Private Limited, Herbal Strategi Homecare Private Limited, Hindustan Herbals Limited, Dhathri Life Sciences Private Limited and 1 more, all in the Healthcare industry (Ayurvedic Products and Services), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).